Skip to main content
Premium Trial:

Request an Annual Quote

Metin Colpan, Peer Schatz, Christian Henry, Cedric Loiret-Bernal, Michael Kranda, Paul Allen, Robert Rosenthal


Metin Colpan, CEO of Venlo, Netherlands-based Qiagen will transition to senior technology advisor and will join the supervisory board beginning on Jan. 1, the company said this week. Peer Schatz, who has served as chief financial officer of Qiagen for the past 11 years, has been named CEO.

Christian Henry the former vice president, finance, and corporate controller of Affymetrix, has been appointed chief financial officer of

Cedric Loiret-Bernal, the co-founder and former CEO of Geneva Proteomics, has been named president and CEO of NanoInk, the Chicago firm said last week. Loiret-Bernal co-founded GeneProt in 2000, but left last April, and joined CDP Capital Technology Ventures, a Canadian institutional investment firm, where he served as a venture advisor for US life sciences investments.

Before founding GeneProt, Loiret-Bernal was a senior investment analyst and partner at Brinson Partners, which is now part of UBS Global Asset Management, and has also held positions in strategic planning at Abbott Laboratories and in marketing at Haemonetics and Porges-Synthelabo.

Michael Kranda has joined Vulcan, the investment and project management company for the assets of Microsoft co-founder Paul Allen, to direct life sciences investment, the firm said last week. Kranda is the former CEO of Oxford Glycosciences, which was acquired by UK biotech firm Celltech in June. Prior to that, he was president, COO and director at Immunex.

Robert Rosenthal has been appointed president and chief executive officer of TekCel, the Hopkinton, Mass., liquid handling and sample management tools company said. Rosenthal was formerly president of PerkinElmer’s instrument’s division. Prior to that, Rosenthal was president and CEO of Thermo Optek, an instrument company that went public in 1996. Before that, he was president of Nicolet Instrument, a subsidiary of Thermo Instruments. Rosenthal replaces Herbert Hooper, who is an operating partner at Ampersand Ventures, the lead investor in the company, and was serving as interim CEO of TekCel since August 2003.

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.